AU2016346304B2 - Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders - Google Patents

Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders Download PDF

Info

Publication number
AU2016346304B2
AU2016346304B2 AU2016346304A AU2016346304A AU2016346304B2 AU 2016346304 B2 AU2016346304 B2 AU 2016346304B2 AU 2016346304 A AU2016346304 A AU 2016346304A AU 2016346304 A AU2016346304 A AU 2016346304A AU 2016346304 B2 AU2016346304 B2 AU 2016346304B2
Authority
AU
Australia
Prior art keywords
dendrimer
nec
nac
composition
dendrimers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016346304A
Other languages
English (en)
Other versions
AU2016346304A1 (en
Inventor
David HACKAM
Sujatha Kannan
Diego F. Nino
Kannan Rangaramanujam
Fan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2016346304A1 publication Critical patent/AU2016346304A1/en
Application granted granted Critical
Publication of AU2016346304B2 publication Critical patent/AU2016346304B2/en
Priority to AU2020200143A priority Critical patent/AU2020200143B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016346304A 2015-10-29 2016-10-26 Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders Active AU2016346304B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200143A AU2020200143B2 (en) 2015-10-29 2020-01-08 Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248063P 2015-10-29 2015-10-29
US62/248,063 2015-10-29
PCT/US2016/058763 WO2017074993A1 (en) 2015-10-29 2016-10-26 Denderimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200143A Division AU2020200143B2 (en) 2015-10-29 2020-01-08 Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders

Publications (2)

Publication Number Publication Date
AU2016346304A1 AU2016346304A1 (en) 2018-05-10
AU2016346304B2 true AU2016346304B2 (en) 2019-11-07

Family

ID=57286827

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016346304A Active AU2016346304B2 (en) 2015-10-29 2016-10-26 Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
AU2020200143A Active AU2020200143B2 (en) 2015-10-29 2020-01-08 Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200143A Active AU2020200143B2 (en) 2015-10-29 2020-01-08 Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders

Country Status (8)

Country Link
US (2) US20170119897A1 (enExample)
EP (1) EP3368028B1 (enExample)
JP (2) JP7108306B2 (enExample)
CN (1) CN108289872B (enExample)
AU (2) AU2016346304B2 (enExample)
CA (1) CA3003628C (enExample)
ES (1) ES3012645T3 (enExample)
WO (1) WO2017074993A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
EP3368028B1 (en) * 2015-10-29 2024-12-11 The Johns Hopkins University Denderimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2019005966A1 (en) * 2017-06-29 2019-01-03 Massachusetts Institute Of Technology CONJUGATED DRUG DENDRIMER FOR EXTENDED INTRA-ARTICULAR ADMINISTRATION
CN111615528A (zh) * 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
WO2020146573A1 (en) * 2019-01-09 2020-07-16 The Johns Hopkins University Compounds and treatments that enhance enteric nervous system function
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
WO2021113651A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
CN116075322A (zh) 2020-04-24 2023-05-05 阿什瓦塔治疗股份有限公司 用于治疗重度急性呼吸窘迫综合征的树枝状大分子组合物和方法
CN118948905A (zh) * 2024-10-15 2024-11-15 杭州菌吾细研生物科技有限公司 植物乳植杆菌Mle-3应用及组合物和复合微生物制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352230A1 (en) * 2013-01-11 2015-12-10 The Regents Of The University Of Michigan Synthesis and isolation of dendrimer based imaging systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
EP2442797B1 (en) 2009-06-15 2020-01-01 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
JP2015526434A (ja) * 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
US10029014B2 (en) * 2013-09-10 2018-07-24 The Research Foundation For The State University Of New York Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery
EP3368028B1 (en) * 2015-10-29 2024-12-11 The Johns Hopkins University Denderimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352230A1 (en) * 2013-01-11 2015-12-10 The Regents Of The University Of Michigan Synthesis and isolation of dendrimer based imaging systems

Also Published As

Publication number Publication date
CA3003628A1 (en) 2017-05-04
AU2016346304A1 (en) 2018-05-10
WO2017074993A1 (en) 2017-05-04
JP2018531962A (ja) 2018-11-01
JP7108306B2 (ja) 2022-07-28
CN108289872A (zh) 2018-07-17
EP3368028B1 (en) 2024-12-11
AU2020200143A1 (en) 2020-01-30
US20170119897A1 (en) 2017-05-04
US20220080056A1 (en) 2022-03-17
EP3368028A1 (en) 2018-09-05
CA3003628C (en) 2022-05-03
ES3012645T3 (en) 2025-04-09
JP2022125314A (ja) 2022-08-26
EP3368028C0 (en) 2024-12-11
CN108289872B (zh) 2021-04-02
AU2020200143B2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
AU2020200143B2 (en) Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
AU2022221454B2 (en) Dendrimer delivery system and methods of use thereof
US20250205369A1 (en) Dendrimer compositions and use in treatment of neurological and cns disorders
EP2442797B1 (en) Dendrimer based nanodevices for therapeutic and imaging purposes
JP2017149960A (ja) 可逆的に架橋されたミセル系
Lee et al. Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 paclitaxel groups and 8 PEG groups
CN108430514A (zh) 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
Benchaala et al. Folate-functionalized dendrimers for targeting Chlamydia-infected tissues in a mouse model of reactive arthritis
CA3189682A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
CN119053344A (zh) 用于靶向递送治疗剂至神经元的树枝状聚合物组合物
US20250352653A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
Dar et al. Neuron‐targeted 2‐deoxyglucose‐dendrimer‐rosiglitazone nanotherapy mitigates neuroinflammation and cognitive deficits in pediatric traumatic brain injury

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ DENDRIMER COMPOSITIONS AND USE IN TREATMENT OF NECROTIZING ENTEROCOLITIS AND OTHER GASTROINTESTINAL DISORDERS

FGA Letters patent sealed or granted (standard patent)